Description:
Background
Driven by the urgent need for COVID-19 vaccines, Northeastern University researchers are exploiting cryogel technology to leverage the cryogel vaccine against SARS-CoV-2 subunits. The proposed invention describes an injectable cryogel-based vaccine to recruit and activate immune cells against SARS-CoV-2 subunits (e.g., S-protein, N-protein).
 
Technology Overview
An injectable therapeutic vaccine platform comprises a biodegradable and porous cryogel. This platform will function prophylactically and therapeutically through an optimized formulation, sustained delivery of immunomodulatory factors, and control of immune signaling (i.e., recruitment, activation/training, and release of immune cells). The injectable cryogel vaccine contains immunomodulatory factors, including SARS-CoV-2 subunits (S-protein, N-protein), adjuvants (CpG-ODN + lipidic immunomodulators), and a DC-recruiting factor (GM-CSF).
 
Benefits
- A vaccine to treat COVID-19 prophylactically and therapeutically 
- A vaccine to target various SARS-CoV-2 subunits 
- Controlled delivery of immunomodulatory factors 
- A platform compatible with various adjuvants and antigens, both commercially available and new ones
 
Applications
- A prophylatic cryogel-based COVID-19 vaccine 
- A therapeutic cryogel-based COVID-19 vaccine 
- Cryogel vaccines for other infectious diseases (e.g. HIV, Malaria, Herpes, etc)
 
Opportunity
- License
- Partnering
- Research collaboration
Patent Information:
Category(s):
Diagnostics
Biotechnology
For Information, Contact:
Mark Saulich
Associate Director of Commercialization
Northeastern University
m.saulich@northeastern.edu
Inventors:
Sidi Bencherif
Keywords:
Biomaterials
COVID-19
Vaccine